Literature DB >> 18021296

Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.

Begoña Caneda-Ferrón1, Luigi A De Girolamo, Teresa Costa, Katy E Beck, Robert Layfield, E Ellen Billett.   

Abstract

Mitochondrial impairment, glutathione depletion and oxidative stress have been implicated in the pathogenesis of Parkinson's disease (PD), linked recently to proteasomal dysfunction. Our study analysed how these factors influence the various activities of the proteasome in human SH-SY5Y neuroblastoma cells treated with the PD mimetics MPP+ (a complex 1 inhibitor) or dopamine. Treatment with these toxins led to dose- and time-dependent reductions in ATP and glutathione and also chymotrypsin-like and post-acidic like activities; trypsin-like activity was unaffected. Antioxidants blocked the effects of dopamine, but not MPP+, suggesting that oxidative stress was more important in the dopamine-mediated effects. With MPP+, ATP depletion was a prerequisite for loss of proteasomal activity. Thus in a dopaminergic neuron with complex 1 dysfunction both oxidative stress and ATP depletion will contribute independently to loss of proteasomal function. We show for the first time that addition of MPP+ or dopamine to purified samples of the human 20S proteasome also reduced proteasomal activities; with dopamine being most damaging. As with toxin-treated cells, chymotrypsin-like activity was most sensitive and trypsin-like activity the least sensitive. The observed differential sensitivity of the various proteasomal activities to PD mimetics is novel and its significance needs further study in human cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021296     DOI: 10.1111/j.1471-4159.2007.05130.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease.

Authors:  Xinglong Wang; Bo Su; Wanhong Liu; Xiaohua He; Yuan Gao; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Aging Cell       Date:  2011-06-14       Impact factor: 9.304

3.  Inhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways.

Authors:  Juliana Navarro-Yepes; Annadurai Anandhan; Erin Bradley; Iryna Bohovych; Bo Yarabe; Annemieke de Jong; Huib Ovaa; You Zhou; Oleh Khalimonchuk; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Mol Neurobiol       Date:  2015-09-26       Impact factor: 5.590

4.  The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Authors:  Matthew J Benskey; Fredric P Manfredsson; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2014-11-20       Impact factor: 4.294

5.  Variable toxicological response to the loss of OXPHOS through 1-methyl-4-phenylpyridinium-induced mitochondrial damage and anoxia in diverse neural immortal cell lines.

Authors:  Elizabeth A Mazzio; Youssef I Soliman; Karam F A Soliman
Journal:  Cell Biol Toxicol       Date:  2010-04-18       Impact factor: 6.691

6.  Evidence for synergism between cell death mechanisms in a cellular model of neurodegeneration in Parkinson's disease.

Authors:  C J Yong-Kee; R Warre; P P Monnier; A M Lozano; J E Nash
Journal:  Neurotox Res       Date:  2012-04-20       Impact factor: 3.911

Review 7.  Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies.

Authors:  Belém Sampaio-Marques; Paula Ludovico
Journal:  Biomolecules       Date:  2015-05-04

8.  α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.

Authors:  Brent J Ryan; Lara L Lourenço-Venda; Mark J Crabtree; Ashley B Hale; Keith M Channon; Richard Wade-Martins
Journal:  Free Radic Biol Med       Date:  2013-10-19       Impact factor: 7.376

Review 9.  Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?

Authors:  Yuganthini Vijayanathan; Siong Meng Lim; Maw Pin Tan; Fei Ting Lim; Abu Bakar Abdul Majeed; Kalavathy Ramasamy
Journal:  Neurotox Res       Date:  2020-11-03       Impact factor: 3.911

Review 10.  Precise assembly and regulation of 26S proteasome and correlation between proteasome dysfunction and neurodegenerative diseases.

Authors:  Eunju Im; Kwang Chul Chung
Journal:  BMB Rep       Date:  2016-09       Impact factor: 4.778

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.